![](/img/cover-not-exists.png)
995PDPHASE II STUDY OF LENVATINIB (LEN), A MULTI-TARGETED TYROSINE KINASE INHIBITOR, IN PATIENTS (PTS) WITH ALL HISTOLOGIC SUBTYPES OF ADVANCED THYROID CANCER (DIFFERENTIATED, MEDULLARY AND ANAPLASTIC)
Takahashi, S., Tahara, M., Kiyota, N., Yamazaki, T., Chayahara, N., Nakano, K., Inagaki, R., Toda, K., Enokida, T., Minami, H., Imamura, Y., Sasaki, T., Suzuki, T., Fujino, K., Dutcus, C.Volume:
25
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdu340.10
Date:
September, 2014
File:
PDF, 64 KB
2014